Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

eatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.
For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation our expectation regarding continued growth of Esbriet revenues in Germany, other EU countries and Canada, our anticipated timing of concluding pricing and reimbursement discussions and/or initiating commercial launches for Esbriet in Canada, France, Italy, Spain, the United Kingdom and other EU countries, the estimated size of the patient population in Canada suffering from IPF and our expectations with respect to Canada of securing coverage from private insurance plans and reimbursement from public (provincial) drug reimbursement plans including the timing thereof, our expectations regarding headcount in our Canadian commercial organization and the functions of such personnel, and our expectation regarding the timing and nature of full enrollment in, and results of, the ASCEND study and the prospects of success thereof.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune ass
'/>"/>

SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune To Release Third Quarter Financial Results On November 7
2. InterMune To Present At JMP Securities Healthcare Conference
3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
4. InterMune to Present at J. P. Morgan Healthcare Conference
5. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
8. Patient Safety Technologies Reports Third Quarter 2012 Results
9. PDI Reports 2012 Third Quarter Financial Results
10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
11. Neurocrine Biosciences Reports Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014 Synageva BioPharma ... a biopharmaceutical company developing therapeutic products for rare ... Bazemore as Chief Operating Officer.  Reporting directly ... Chief Executive Officer, Robert will oversee the planned ... sebelipase alfa for LAL Deficiency, and will have ...
(Date:9/21/2014)... University of Basel in Switzerland have succeeded in ... molecule for the first time. These extremely weak ... molecular properties and may also contribute to the ... results were published in the scientific journal ... the interaction between matter and light, is probably ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 Chemical ... global challenges such as clean air and safe ... and natural products. Chemists, environmentalists, food scientists, educators, ... the research in the field of Chemistry for ... Chemical Sciences is one of the fastest emerging ...
(Date:9/20/2014)... 2014 HealthTronics, Inc. , ... radiology products and services, has signed a distribution ... Clinicon Corporation for its high precision laser ... minimally invasive, mobile, surgical technology—offering more choices for ... agreement, HealthTronics will make available Clinicon’s FDA-cleared SureLase™ ...
Breaking Biology Technology:Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Uncovering the forbidden side of molecules 2Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3
... Food and Drug Administration is changing. However, is it ... answer is a qualified "yes", but the demands on ... The growing demands of scientific discovery, regulatory needs, and ... FDA. , ,The explosion in biotechnology and other scientific ...
... just turned one! It is both rewarding and inspirational to ... 12 months of online publishing. , ,According to Alexa ... has obtained the largest readership in terms of reach, ... feature websites in the Midwest. WTN is read beyond Wisconsin ...
... special breed of person to staff customer support centers. These ... a breakdown of a complicated computer system, and then be ... the problem. Finding these very talented people is not an ... for a high degree of technical aptitude. But there is ...
Cached Biology Technology:Fast Track: Topics for Consideration 2WTN's First Year 2Hope For Some U.S. Tech Workers 2Hope For Some U.S. Tech Workers 3
(Date:9/22/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... mobile commerce market, issues the following corporate shareholder update ... Letter from the CEO : ... funding and joined the NASDAQ to support ramping of ... biometric and authentication products and services. This strategic achievement positions ...
(Date:9/22/2014)... 7,000 geoscientists will gather in Vancouver, British Columbia, Canada, ... America,s 126th Annual Meeting & Exposition on 19-22 October ... transportation of crude oil, earthquake prediction problems, and how ... and Tribulations of Life on an Active Subduction Zone, ... , A broad range of topics will be presented ...
(Date:9/21/2014)... United Nations General Assembly events focussed on ways to ... children, Grand Challenges Canada, funded by the Government of ... bold ideas to address this challenge. , The novel ... Bangladeshi mothers working in garment factories to express, pasteurize ... reducing absenteeism due to child illnesses, and lowering baby ...
Breaking Biology News(10 mins):NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Geoscience topics in the spotlight -- Vancouver, BC 2Geoscience topics in the spotlight -- Vancouver, BC 3Geoscience topics in the spotlight -- Vancouver, BC 4Geoscience topics in the spotlight -- Vancouver, BC 5Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 2Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 3Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 4Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 5Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 6Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 7Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 8Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 9Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 10Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 11Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 12Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 13Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 14Canada funds 22 innovative projects to help save 'Every Woman, Every Child' 15
... WILLIAMSTOWN, Mass., July 10, 2008 -- Thomas E. Smith, ... awarded a $217,710 three-year grant by the National Cancer ... "Asymmetric Methods for the Synthesis of Pyran-Based Anticancer Natural ... of new methods that will allow for the efficient ...
... a million electrical signals pulsing through your body. At the ... the ion channel. A new study by researchers from ... a meter in ion channels. This movement is critical to ... close in response to changes in voltage across the membrane. ...
... a self-assembled monolayer of a polychlorotriphenyl methyl radical ... behaves as an electroactive switch with optical and ... be made to form ordered layers on a ... Science Foundation (ESF) through the EUROCORES programne SONS ...
Cached Biology News:Researchers catch ion channels in their opening act 2Researchers catch ion channels in their opening act 3Multitasking nanotechnology 2Multitasking nanotechnology 3
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
... LIGHT. Useful in cell activation experiments when calcium dose-response ... Soluble in DMSO or EtOH. For use ... in DMSO is recommended. Microliter amounts of this solution ... mixing (e.g. 10 μl into 5 ml of H ...
Monoclonal antibodies conjugated with rhodamine...
... Rhodopsin Rhodopsin is a glycoprotein which ... amphibians, and reptiles. The rhodopsin protein is ... retina. Immunogen: Membrane preparation ... This antibody specifically labels the axons ...
Biology Products: